US5097020A
(en)
*
|
1983-07-05 |
1992-03-17 |
The University Of Rochester |
Immunogenic conjugates
|
US5360897A
(en)
*
|
1981-08-31 |
1994-11-01 |
The University Of Rochester |
Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
|
US4673574A
(en)
*
|
1981-08-31 |
1987-06-16 |
Anderson Porter W |
Immunogenic conjugates
|
US4902506A
(en)
*
|
1983-07-05 |
1990-02-20 |
The University Of Rochester |
Immunogenic conjugates
|
US4663160A
(en)
*
|
1983-03-14 |
1987-05-05 |
Miles Laboratories, Inc. |
Vaccines for gram-negative bacteria
|
US4761283A
(en)
*
|
1983-07-05 |
1988-08-02 |
The University Of Rochester |
Immunogenic conjugates
|
US4762713A
(en)
*
|
1983-07-05 |
1988-08-09 |
The University Of Rochester |
Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
|
US4695624A
(en)
*
|
1984-05-10 |
1987-09-22 |
Merck & Co., Inc. |
Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
|
US4808700A
(en)
*
|
1984-07-09 |
1989-02-28 |
Praxis Biologics, Inc. |
Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
|
SE8405493D0
(sv)
*
|
1984-11-01 |
1984-11-01 |
Bror Morein |
Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
|
NZ214503A
(en)
*
|
1984-12-20 |
1990-02-26 |
Merck & Co Inc |
Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
|
US6024964A
(en)
*
|
1985-06-24 |
2000-02-15 |
Hoechst Aktiengesellschaft |
Membrane anchor/active compound conjugate, its preparation and its uses
|
US6074650A
(en)
*
|
1985-06-24 |
2000-06-13 |
Hoechst Aktiengesellschaft |
Membrane anchor/active compound conjugate, its preparation and its uses
|
US4762822A
(en)
*
|
1985-08-08 |
1988-08-09 |
Ettinger Anna C |
Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
|
US4707543A
(en)
*
|
1985-09-17 |
1987-11-17 |
The United States Of America As Represented By The Secretary Of The Army |
Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
|
US4681761A
(en)
*
|
1985-10-24 |
1987-07-21 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine
|
AU619443B2
(en)
*
|
1986-04-21 |
1992-01-30 |
Bioenterprises Pty. Ltd. |
Immunopotentiation
|
CA1331355C
(en)
*
|
1986-04-21 |
1994-08-09 |
Bioenterprises Pty. Ltd |
Immunopotentation
|
US5374426A
(en)
*
|
1986-09-03 |
1994-12-20 |
University Of Saskatchewan |
Rotavirus nucleocapsid protein VP6 in vaccine compositions
|
US5300632A
(en)
*
|
1986-11-18 |
1994-04-05 |
Research Foundation Of State University Of New York |
Method for purifying an outer membrane protein of Haemophilus influenzae
|
NZ223009A
(en)
*
|
1986-12-31 |
1990-06-26 |
Nl Rivm Of Thoven |
Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
|
US5976839A
(en)
*
|
1987-03-13 |
1999-11-02 |
Bioenterprises Pty Limited |
Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
|
US5785973A
(en)
*
|
1988-02-01 |
1998-07-28 |
Praxis Biologics, Inc. |
Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
|
US5204098A
(en)
*
|
1988-02-16 |
1993-04-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Polysaccharide-protein conjugates
|
US7118757B1
(en)
*
|
1988-12-19 |
2006-10-10 |
Wyeth Holdings Corporation |
Meningococcal class 1 outer-membrane protein vaccine
|
EP0407037B1
(en)
*
|
1989-06-12 |
1994-09-21 |
Merck & Co. Inc. |
Process for removing bacterial endotoxin from gram-negative polysaccharides
|
CU22302A1
(es)
*
|
1990-09-07 |
1995-01-31 |
Cigb |
Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
|
CA2047030A1
(en)
*
|
1990-07-19 |
1992-01-20 |
Allen I. Oliff |
Class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties
|
IE912559A1
(en)
*
|
1990-07-19 |
1992-01-29 |
Merck & Co Inc |
The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
|
CA2059693C
(en)
*
|
1991-01-28 |
2003-08-19 |
Peter J. Kniskern |
Polysaccharide antigens from streptococcus pneumoniae
|
CA2059692C
(en)
*
|
1991-01-28 |
2004-11-16 |
Peter J. Kniskern |
Pneumoccoccal polysaccharide conjugate vaccine
|
SK13494A3
(en)
*
|
1991-08-13 |
1994-09-07 |
Biotech Australia Pty Ltd |
Immunostimulation
|
US5314811A
(en)
*
|
1992-07-13 |
1994-05-24 |
Merck & Co., Inc. |
Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
|
US5736146A
(en)
*
|
1992-07-30 |
1998-04-07 |
Yeda Research And Development Co. Ltd. |
Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
|
US6153406A
(en)
*
|
1993-07-23 |
2000-11-28 |
North American Vaccine, Inc. |
Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
|
GB9422096D0
(en)
*
|
1994-11-02 |
1994-12-21 |
Biocine Spa |
Combined meningitis vaccine
|
US6309646B1
(en)
|
1996-05-09 |
2001-10-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
|
JP2004505885A
(ja)
*
|
1998-08-19 |
2004-02-26 |
ノース アメリカン ワクチン, インコーポレイテッド |
N−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
|
US6146902A
(en)
*
|
1998-12-29 |
2000-11-14 |
Aventis Pasteur, Inc. |
Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
|
SK288007B6
(sk)
*
|
2000-06-29 |
2012-10-02 |
Glaxosmithkline Biologicals S. A. |
Multivalent vaccine composition, process for its producing, and its use
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
JP4697706B2
(ja)
|
2002-10-11 |
2011-06-08 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP2191844B1
(en)
|
2003-01-30 |
2014-03-05 |
Novartis AG |
Injectable vaccines against multiple meningococcal serogroups
|
CN103405761A
(zh)
|
2003-10-02 |
2013-11-27 |
诺华疫苗和诊断有限公司 |
多种脑膜炎球菌血清群的液体疫苗
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408977D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Immunising against meningococcal serogroup Y using proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
EP2272531A3
(en)
|
2004-04-30 |
2011-04-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Integration of meningococcal conjugate vaccination
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
US9931397B2
(en)
|
2005-06-27 |
2018-04-03 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CN101378778B
(zh)
|
2005-12-22 |
2013-02-06 |
葛兰素史密丝克莱恩生物有限公司 |
肺炎球菌多糖缀合物疫苗
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
PT2004225E
(pt)
|
2006-03-22 |
2012-05-30 |
Novartis Ag |
Regimes para imunização com conjugados meningocócicos
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
PT2097102E
(pt)
|
2006-09-07 |
2012-08-03 |
Glaxosmithkline Biolog Sa |
Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
US20100074918A1
(en)
|
2007-05-02 |
2010-03-25 |
Jan Poolman |
Vaccine
|
AU2008267208B2
(en)
|
2007-06-26 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
FR2918671B1
(fr)
*
|
2007-07-10 |
2010-10-15 |
Sanofi Pasteur |
Milieu de culture d'haemophilus influenzae type b.
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2462949A3
(en)
|
2007-10-19 |
2012-09-05 |
Novartis AG |
Meningococcal vaccine formulations
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
PT2349520T
(pt)
|
2008-10-27 |
2016-08-16 |
Glaxosmithkline Biologicals Sa |
Método de purificação para hidrato de carbono de estreptococos grupo a
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
AU2009329193A1
(en)
|
2008-12-17 |
2011-07-14 |
Novartis Ag |
Meningococcal vaccines including hemoglobin receptor
|
EP2411048B1
(en)
|
2009-03-24 |
2020-05-06 |
GlaxoSmithKline Biologicals SA |
Adjuvanting meningococcal factor h binding protein
|
JP5668049B2
(ja)
|
2009-03-24 |
2015-02-12 |
ノバルティス アーゲー |
髄膜炎菌h因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
|
BRPI1013780B8
(pt)
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
|
US8926982B2
(en)
*
|
2009-06-01 |
2015-01-06 |
Xuguang Li |
Reagents and methods for detecting influenza virus proteins
|
US20120135037A1
(en)
|
2009-06-01 |
2012-05-31 |
Mizel Steven B |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
CN104650241A
(zh)
|
2009-08-27 |
2015-05-27 |
诺华股份有限公司 |
包括脑膜炎球菌fHBP序列的杂交多肽
|
SG178904A1
(en)
|
2009-09-10 |
2012-04-27 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
CA2779816A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP2519265B1
(en)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011148382A1
(en)
*
|
2010-05-28 |
2011-12-01 |
Biological E Limited |
An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
|
EP2585106A1
(en)
|
2010-06-25 |
2013-05-01 |
Novartis AG |
Combinations of meningococcal factor h binding proteins
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
JP6191082B2
(ja)
|
2011-03-02 |
2017-09-06 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
より低用量の抗原および/またはアジュバントを有する混合ワクチン
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
CN104080479B
(zh)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
包括spr0096和spr2021抗原的运载体分子
|
DK3785730T3
(da)
|
2011-12-06 |
2024-05-06 |
Valneva Austria Gmbh |
Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
EP2797624A1
(en)
|
2011-12-29 |
2014-11-05 |
Novartis AG |
Adjuvanted combinations of meningococcal factor h binding proteins
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Streptococcuspneumoniae抗原の増強された製剤
|
EP2822584A1
(en)
|
2012-03-08 |
2015-01-14 |
Novartis AG |
Combination vaccines with tlr4 agonists
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
JP6324961B2
(ja)
|
2012-09-06 |
2018-05-16 |
ノバルティス アーゲー |
血清群b髄膜炎菌とd/t/pとの組み合わせワクチン
|
JP2015532276A
(ja)
|
2012-10-02 |
2015-11-09 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
非直鎖状糖コンジュゲート
|
CA2886938A1
(en)
|
2012-10-12 |
2014-04-17 |
Glaxosmithkline Biologicals S.A. |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
PL2925355T3
(pl)
|
2012-11-30 |
2018-06-29 |
Glaxosmithkline Biologicals S.A. |
Antygeny pseudomonas i połączenia antygenów
|
CA2899787A1
(en)
|
2013-02-01 |
2014-08-07 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor agonists
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
RS61246B1
(sr)
|
2014-02-28 |
2021-01-29 |
Glaxosmithkline Biologicals Sa |
Modifikovani meningokokni fhbp polipeptidi
|
EP3034516A1
(en)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification of streptococcal capsular polysaccharide
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US20180064801A1
(en)
|
2016-09-02 |
2018-03-08 |
Glaxosmithkline Biologicals Sa |
Vaccines for neisseria gonorrhoeae
|
US11027005B2
(en)
|
2016-10-20 |
2021-06-08 |
Km Biologics Co., Ltd. |
Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
|
CA3044569A1
(en)
|
2016-11-25 |
2018-05-31 |
Glaxosmithkline Biologicals S.A. |
Immunogenic conjugates and use thereof
|
MX2019006105A
(es)
|
2016-11-25 |
2019-08-21 |
Glaxosmithkline Biologicals Sa |
Conjugados de vmen-antigeno y uso de los mismos.
|
EP3551668A1
(en)
|
2016-12-06 |
2019-10-16 |
GlaxoSmithKline Biologicals S.A. |
Purification process for capsular polysaccharide
|
AU2018215585B2
(en)
|
2017-01-31 |
2022-03-17 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
CA3052621A1
(en)
|
2017-02-03 |
2018-08-09 |
Schadeck, Eva Barbara |
Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
|
EP3607967A1
(en)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Modified meningococcal fhbp polypeptides
|
US20220118072A1
(en)
|
2019-02-11 |
2022-04-21 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
JOP20200214A1
(ar)
|
2019-09-03 |
2021-03-03 |
Serum Institute Of India Pvt Ltd |
تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
|
US20220401544A1
(en)
|
2019-09-27 |
2022-12-22 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
EP3799884A1
(en)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
JP2021132644A
(ja)
|
2020-02-21 |
2021-09-13 |
ファイザー・インク |
糖の精製
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
CA3199094A1
(en)
|
2020-10-22 |
2022-04-28 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
US20240000958A1
(en)
|
2020-11-13 |
2024-01-04 |
Glaxosmithkline Biologicals Sa |
Novel carriers and conjugation methods
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202215414D0
(en)
|
2022-10-18 |
2022-11-30 |
Glaxosmithkline Biologicals Sa |
Vaccine
|